temozolomide has been researched along with Leukemia in 11 studies
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 9.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 5.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| " A pilot clinical study indicates that dacarbazine can induce a marked decrease of leukemic blasts in patients affected by acute myelogenous leukemia (AML) with low pretreatment levels of OGAT activity." | 5.08 | Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. ( Bonmassar, E; Caravita, T; D'Atri, S; Franchi, A; Graziani, G; Papa, G; Piccioni, D, 1995) |
| " We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)." | 4.82 | Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005) |
| "treatment with Lomeguatrib (to suppress MGMT activity) and Temozolomide (to kill sensitive blasts and to presumably induce CX in resistant leukaemic cells); (b) immune response recovery phase using interleukin-2 (to possibly restore an immune response and take advantage of the hypothetical, triazene-induced CX)." | 1.34 | Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. ( Alvino, E; Amadori, S; Bonmassar, E; Buccisano, F; Caporaso, P; D'Atri, S; Garbin, A; Marchesi, F; Tirindelli, MC; Toppo, L; Tortorelli, G; Turriziani, M; Venditti, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horton, TM | 2 |
| Jenkins, G | 1 |
| Pati, D | 1 |
| Zhang, L | 1 |
| Dolan, ME | 2 |
| Ribes-Zamora, A | 1 |
| Bertuch, AA | 1 |
| Blaney, SM | 2 |
| Delaney, SL | 1 |
| Hegde, M | 1 |
| Berg, SL | 2 |
| Rizzieri, D | 1 |
| LoRusso, S | 1 |
| Tse, W | 1 |
| Khan, K | 1 |
| Advani, A | 1 |
| Moore, J | 1 |
| Karsten, V | 1 |
| Cahill, A | 1 |
| Gerson, SL | 1 |
| Cipak, L | 1 |
| Su, YW | 1 |
| Chang, MC | 1 |
| Chiang, MF | 1 |
| Hsieh, RK | 1 |
| Katsoulas, A | 1 |
| Rachid, Z | 1 |
| Brahimi, F | 1 |
| McNamee, J | 1 |
| Jean-Claude, BJ | 1 |
| Caporaso, P | 1 |
| Turriziani, M | 2 |
| Venditti, A | 1 |
| Marchesi, F | 1 |
| Buccisano, F | 1 |
| Tirindelli, MC | 1 |
| Alvino, E | 1 |
| Garbin, A | 1 |
| Tortorelli, G | 1 |
| Toppo, L | 1 |
| Bonmassar, E | 5 |
| D'Atri, S | 4 |
| Amadori, S | 1 |
| Thompson, PA | 1 |
| Adamson, PC | 1 |
| Ingle, AM | 1 |
| Delaney, SM | 1 |
| Hedge, M | 1 |
| Weiss, HL | 1 |
| Wu, MF | 1 |
| Tentori, L | 3 |
| Graziani, G | 4 |
| Gilberti, S | 1 |
| Lacal, PM | 2 |
| Piccioni, D | 1 |
| Papa, G | 1 |
| Caravita, T | 1 |
| Franchi, A | 1 |
| Orlando, L | 1 |
| Benincasa, E | 1 |
| Faraoni, I | 1 |
| Franco, D | 1 |
| Serafino, A | 1 |
| Levati, L | 1 |
| Roy, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies[NCT00098436] | Phase 1 | 25 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias[NCT00083070] | Phase 1 | 16 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and Leukemia
| Article | Year |
|---|---|
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
3 trials available for temozolomide and Leukemia
| Article | Year |
|---|---|
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Histor | 2010 |
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; DNA Modi | 2007 |
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cisplatin; Dacarbazine; D | 1995 |
7 other studies available for temozolomide and Leukemia
| Article | Year |
|---|---|
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repai | 2009 |
Novel nonclassical antifolate, 2-[N-(2´-Hydroxyethyl)amino]methyl-3H-quinazolin-4-one, with a potent antineoplastic activity toward leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Cisplatin; Dacarbazine; Female | 2012 |
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Culture Media; Dacarbazine; DNA Damage; Dose-Response Re | 2005 |
Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; DNA Methylation; | 2007 |
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Gene Expression; Humans; Leukemia; Methyl | 1995 |
Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Fragmentation; DNA Methylation; DNA R | 1997 |
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Dacarbazine; DNA Glycosylases; DNA Ligases | 1999 |